All companies
Visit website
NeuEsse Inc.
OperatingHealthcare · Founded 2018
Creating a human skin substitute from soy protein for clinicians to treat patients with wounds, burns and skin injuries
Post-money valuation ⓘ
$10.0M
As of Nov 2022 · from NeuEsse Inc. Common Stock 1 · pre-money + amount raised, not a traded price
Total raised
$10,459
Across 1 round since 2022
Latest share price
$1.43
NeuEsse Inc. Common Stock 1 offering price
Financials
FY2020–FY2021 · from SEC filings · hover any figure for its source$0
−$542K
2020
$0
−$160K
2021
RevenueNet income — beside revenue when positive, below the line when a loss
Metric
FY2020
FY2021
Income statement
Revenue
$0
$0
Cost of goods sold
$0
$0
Net income
-$541,762
-$160,450
Taxes paid
$0
$0
Balance sheet
Cash
$13,594
$1,957
Accounts receivable
$0
$0
Total assets
$219,893
$217,281
Short-term debt
$0
$0
Long-term debt
$0
$35,100
Total liabilities
$0
$35,100
Other
Headcount
—
1
Figures as reported by the issuer in the filing shown on hover. Each year’s pill shows the assurance level of its filed statements — audited, reviewed (CPA review, less than an audit), or unaudited; no pill means the filing didn’t state one. Headcount is the filing’s point-in-time count, not a year-end average. Manually corrected figures are marked “Corrected”.
Valuation over rounds
Post-money = pre-money + amount raised · caps marked$10.0M
post-money
NeuEsse Inc. Common Stock 1
A dashed amber step is a SAFE/note valuation cap — a conversion ceiling agreed for that instrument, not a priced valuation of the company. Steps are not comparable across bases.
Fundraising history
Raised $10.5K / $1.1MPost-money $10M
Reg CF annual-report compliance
Delinquent
Filed 0 of 4 annual reports (FY2022–FY2025)
Missing: 2022, 2023, 2024, 2025
Reg CF issuers must file a Form C-AR each year until a Rule 202(b) termination trigger is met.
SEC filings
Source: ManualCIK 0001943294Share price $1.43
About this data. Figures are compiled from public sources — SEC EDGAR filings (Form C, C-AR, 1-A, 1-K) and funding-platform pages — and may be delayed, incomplete, or restated by the issuer. Financial statements are as reported by the issuer; each year is labeled with its assurance level (audited / reviewed / unaudited). A valuation cap is the conversion ceiling of a SAFE or convertible note, not an agreed company valuation; post-money figures are computed as pre-money plus amount raised and are not a traded price. Crowdonomics is not a broker-dealer, funding portal, or investment adviser; nothing here is investment advice or an offer to sell securities. Verify all figures against the linked EDGAR filings.